Brent Sabatini, the Senior Vice President and Chief Accounting Officer at Vir Biotechnology, Inc. (NASDAQ:VIR), recently sold 1,562 shares of the company's common stock. According to InvestingPro data ...
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of ...
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results